Yang CL - Search Results

1

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.

Cheng Y, Li H, Zhang L, Liu JJ, Yang CL, Zhang S. Cheng Y, et al. Among authors: yang cl. Chin Med J (Engl). 2021 Jun 16;134(15):1780-1788. doi: 10.1097/CM9.0000000000001560. Chin Med J (Engl). 2021. PMID: 34133356 Free PMC article. Review.

2

[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].

Ma L, Chen Y, Yang C, Jiang H, Zhu J, Cheng Y. Ma L, et al. Zhonghua Zhong Liu Za Zhi. 2015 Jan;37(1):29-32. Zhonghua Zhong Liu Za Zhi. 2015. PMID: 25877315 Chinese.

3

[Research Progress of Immunotherapy for Brain Metastases in Patients  with Drive Gene Negative NSCLC].

Zhang S, Liu J, Yang C, Li S, Cheng Y. Zhang S, et al. Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):610-614. doi: 10.3779/j.issn.1009-3419.2018.08.06. Zhongguo Fei Ai Za Zhi. 2018. PMID: 30172268 Free PMC article. Review. Chinese.

4

Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.

Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y. Liu J, et al. J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8. J Clin Lab Anal. 2019. PMID: 31282096 Free PMC article.

5

The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.

Li S, Zhang S, Liu J, Yang C, Zhang L, Cheng Y. Li S, et al. J Thorac Dis. 2019 Nov;11(11):4453-4463. doi: 10.21037/jtd.2019.11.12. J Thorac Dis. 2019. PMID: 31903233 Free PMC article.

6

Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J, Zhang S, Yang C, Ren X, Cheng Y. Zhang L, et al. Thorac Cancer. 2020 May;11(5):1170-1179. doi: 10.1111/1759-7714.13370. Epub 2020 Mar 5. Thorac Cancer. 2020. PMID: 32134200 Free PMC article.

7

Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.

Cheng Y, Ma L, Liu Y, Zhu J, Xin Y, Liu X, Wang Y, Zhang T, Yang C, Wang S, Cui H, Zhang L, Dai J, Shao L, Lin J, Ye J, Liu H. Cheng Y, et al. Lung Cancer. 2020 Jul;145:63-70. doi: 10.1016/j.lungcan.2020.04.004. Epub 2020 Apr 17. Lung Cancer. 2020. PMID: 32408134

8

[Highlights of PAPR Inhibitors in Small Cell Lung Cancer].

Zhang S, Liu J, Yang C, Zhang L, Li S, Bao H, Cheng Y. Zhang S, et al. Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):806-810. doi: 10.3779/j.issn.1009-3419.2020.102.19. Epub 2020 Aug 5. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32752582 Free PMC article. Review. Chinese.

9

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.

Liu J, Li S, Zhang S, Yang C, Zhang L, Zhang B, Cheng Y, Wang C. Liu J, et al. J Thorac Dis. 2020 Oct;12(10):5765-5773. doi: 10.21037/jtd-20-755. J Thorac Dis. 2020. PMID: 33209408 Free PMC article.

10

Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.

Zhang S, Li S, Liu J, Yang C, Zhang L, Bao H, Cheng Y. Zhang S, et al. Clin Lung Cancer. 2022 Mar;23(2):159-169. doi: 10.1016/j.cllc.2021.06.001. Epub 2021 Jun 13. Clin Lung Cancer. 2022. PMID: 34247986

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

847 results

Search Page

Filters